

risankizumab-rzaa subcutaneous injection (SKYRIZI)

Diagnoses Considered for Coverage:

- Plaque Psoriasis (PsO)
- Psoriatic Arthritis (PsA)
- Crohn's Disease

Coverage Criteria:

For diagnosis of moderate to severe Plaque Psoriasis:

- Prescribed by or in consultation with a rheumatologist or dermatologist, **and**
- Patient is at least 18 years old, **and**
- Inadequate response, intolerable side effect, or contraindication to one of the following: methotrexate, cyclosporine (Neoral), acitretin (Soriatane), **or** PUVA/UVB **and**
- Not being used in combination with Otezla or another targeted biologic, **and**
- Dose does not exceed 150 mg SQ given on week #0, #4, and #16, **and**
- One of the following:
 - Baseline PASI score is 10 or more prior to initiating targeted immunological therapy (eg. Enbrel, Enbrel mini, Hadlima, Humira, Stelara, Cosentyx, Otezla, Taltz), **or**
 - Baseline BSA is 3% or more prior to initiating biological therapy (eg. Enbrel, Enbrel mini, Hadlima, Humira, Stelara, Cosentyx, Otezla, Taltz), **or**
 - Sensitive area is involved (i.e. groin, face, etc.), **or**
 - Disease is otherwise debilitating.

Coverage Duration: 24 weeks

REAUTHORIZATION

- Patient has shown improvement in the baseline PASI (or BSA if provided on initial request) score **and**
- Not being used in combination with other targeted immunotherapies (i.e. anti-TNFs, interleukin inhibitors, Otezla), **and**
- Dose does not exceed 150 mg SQ given once every 12 weeks.

Coverage Duration: one year

For diagnosis of psoriatic arthritis:

- Prescribed by or in consultation with a rheumatologist, **and**
- Inadequate response or intolerable side effect with one DMARD agent **OR**

patient has a medical reason why methotrexate, leflunomide, and sulfasalazine cannot be used, **and**

- Not being used in combination with other targeted immunotherapies (i.e. anti-TNFs, interleukin inhibitors, Otezla, JAK inhibitors), **and**
- Dose does not exceed 150 mg SQ given on week #0, #4, and every 12 weeks thereafter.

Coverage Duration: one year

For diagnosis of moderate to severe Crohn's disease:

- Patient is at least 18 years old, **and**
- Not being used in combination with other targeted immunomodulators (i.e. anti-TNFs, interleukin inhibitors), **and**
- Dose does not exceed 360 mg subcutaneous injection every 8 weeks, **and**
- Being used for SC maintenance therapy following IV induction dosing.

Coverage Duration: one year

Effective Date: 01/03/2024